Pressemitteilungen zu dem Thema inflammatory


Unterkategorien

PresseMitteilungen zu dem Schlagwort inflammatory


NJ Holistic Doctor Michael Rothman Discusses Chronic Inflammatory Disease

Wall, NJ and patients treat the symptoms without ever really finding the underlying causes. Dr. Rothman discusses many of the potential causes of CIRS, including sick building syndrome, as well as metabolic disorders. As part of his discussion, Dr. Rothman looks at the dozens of potential secondary symptoms that can point to CIRS. Dr. Rothman The article, published his website at http://mdwellnessmd.com/blog/post/chronic-inflammatory-response-syndrome-the-underlying-cause-of-many-chronic-dis ...


14.03.2018

Vitality Biopharma Completes Pivotal GMP Manufacturing Agreements for Cannabinoid Pharmaceuticals

LOS ANGELES, CA -- (Marketwired) -- 11/01/17 -- (OTCQB: VBIO) ("Vitality Biopharma," "Vitality," or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced completion of pivotal manufacturing agreements that enable the production of clinical-grade cannabinoid pharmaceuticals at its R&D facili ...


01.11.2017

Vitality Biopharma Announces Positive Results for Multiple Cannabinoid Drug Formulations in Treatment of IBD

LOS ANGELES, CA -- (Marketwired) -- 10/19/17 -- (OTCQB: VBIO) ("Vitality" or the "Company"), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced additional positive preclinical efficacy results for the treatment of colitis.Vitality Biopharma has developed a new class of cannabinoid prodrugs, known as cannabosides, wh ...


19.10.2017

Vitality Biopharma Announces Publication of International PCT Patent Filing for Cannabinoid Pharmaceuticals

LOS ANGELES, CA -- (Marketwired) -- 10/16/17 -- (OTCQB: VBIO) ("Vitality" or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced the publication of an international PCT patent application that covers a new class of cannabinoid pharmaceuticals.The publication of the international patent filing is the fi ...


16.10.2017

Vitality Biopharma Achieves Cannabinoid Pharmaceutical Biosynthesis Breakthrough

LOS ANGELES, CA -- (Marketwired) -- 10/04/17 -- (OTCQB: VBIO) ("Vitality Biopharma", "Vitality", or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced the achievement of a biosynthesis breakthrough.Vitality has developed a proprietary biosynthesis technology that can modify cannabinoids in o ...


04.10.2017

Vitality Biopharma Receives Updated SeeThruEquity Price Target of $2.40

LOS ANGELES, CA -- (Marketwired) -- 09/27/17 -- (OTCQB: VBIO) ("Vitality", "Vitality Biopharma", or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, is pleased to advise that SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, ...


27.09.2017

Asana Medical, Inc. to Present as Innovation Challenge Finalist at RESI Boston Conference 2017

MIAMI LAKES, FL -- (Marketwired) -- 09/11/17 -- ., ("Asana," the "Company"), a regenerative medicine company developing a novel treatment for Ulcerative Colitis, is pleased to announce that it has been selected as an Innovation Challenge Finalist and will present at the in Boston, Massachusetts on Tuesday, September 26th, 2017. The RESI (Redefining Early Stage Investments) Conference is an investor conference for early-stage life science companies, and is being held at the ...


11.09.2017

Dr. Susan G. Manella Joins Asana''s Medical Advisory Board

MIAMI LAKES, FL -- (Marketwired) -- 08/24/17 -- ., ("Asana," the "Company"), a regenerative medicine company that is developing a novel treatment for Inflammatory Bowel Disease ("IBD"), including Ulcerative Colitis and Crohn''s Disease, is pleased to announce that Dr. Susan G. Manella has accepted the Company''s offer to join its Medical Advisory Board. Dr. Manella will assume the board''s leadership role in managing information flow a ...


24.08.2017

Vitality Biopharma to Present at The MoneyShow San Francisco Conference

LOS ANGELES, CA -- (Marketwired) -- 08/23/17 -- (OTCQB: VBIO) ("Vitality", "Vitality Biopharma", or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, is pleased to provide a presentation and participate in a cannabis industry panel session at the MoneyShow San Francisco investment conference.Company CEO Ro ...


23.08.2017

Vitality Biopharma Closes $1 Million Private Placement

LOS ANGELES, CA -- (Marketwired) -- 08/02/17 -- (OTCQB: VBIO) ("Vitality", "Vitality Biopharma", or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, is pleased to advise that on July 28, 2017, the Company closed on a $1 million private placement.As previously described on the Company''s Current ...


02.08.2017

Vitality Biopharma Releases Positive Results for Treatment of Inflammatory Bowel Disease

LOS ANGELES, CA -- (Marketwired) -- 07/19/17 -- (OTCQB: VBIO) ("Vitality" or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced positive preclinical efficacy results for its gut-targeted cannabosides in the treatment of colitis.Vitality Biopharma has developed a new class of cannabinoid prodrugs, know ...


19.07.2017

Vitality Biopharma Advisor to Present Pediatric IBD Case Study at ICRS2017 in Montreal

LOS ANGELES, CA -- (Marketwired) -- 06/21/17 -- (OTCQB: VBIO) ("Vitality Biopharma," "Vitality", or the "Company"), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, announced today that Company Advisor Dr. Natasha Ryz will be presenting at an international research symposium in Montréal, Canada.Dr. Ryz will provide a po ...


21.06.2017

Vitality Biopharma to Present at the 7th Annual LD Micro Invitational

LOS ANGELES, CA -- (Marketwired) -- 05/30/17 -- (OTCQB: VBIO) ("Vitality Biopharma", "Vitality", or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it will be presenting at the 7th Annual LD Micro Invitational in Los Angeles.The corporate presentation is on Tuesday, June 6th at 9:00 ...


30.05.2017

Vitality Biopharma Announces Positive Results for Cannabinoid Antibiotics

LOS ANGELES, CA -- (Marketwired) -- 05/10/17 -- (OTCQB: VBIO) ("Vitality" or the "Company"), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it has obtained positive results demonstrating antimicrobial activity of cannabinoids and filed for patent protection on the use of cannabinoid compounds for the treatme ...


10.05.2017

Vitality Biopharma Adds Key Clinical Advisors in Gastroenterology

LOS ANGELES, CA -- (Marketwired) -- 05/03/17 -- (OTCQB: VBIO) ("Vitality Biopharma," "Vitality", or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, is pleased to announce and welcomes the appointments of Dr. Douglas A. Drossman and Dr. Mark Gerich as clinical advisors with expertise in gastroenterology a ...


03.05.2017

Vitality Biopharma Releases Clinical Report of Cannabinoid Therapy for Pediatric IBD

LOS ANGELES, CA -- (Marketwired) -- 04/20/17 -- (OTCQB: VBIO) ("Vitality Biopharma", "Vitality", or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced the release of one of the first clinical reports detailing the ability of cannabinoid therapy to induce remission in a pediatric inflammatory ...


20.04.2017

Vitality Biopharma Appoints Pharma Industry Veteran to Advance Cannabosides Regulatory Development

LOS ANGELES, CA -- (Marketwired) -- 04/12/17 -- (OTCQB: VBIO) ("Vitality" or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced the appointment of Tracy Rockney, J.D., Co-Founder & Chief Operating Officer, OneSource Regulatory, to the position of Senior Regulatory Advisor.Tracy Rockney, J.D. was f ...


12.04.2017

Vitality Biopharma Announces International Patent Filing for Neural Repair Treatments

LOS ANGELES, CA -- (Marketwired) -- 04/05/17 -- (OTCQB: VBIO) ("Vitality" or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced the filing of an international patent application in March 2017 that describes compounds discovered to be effective in a drug screening model of neural repair.The underlying ...


05.04.2017

Vitality Biopharma Announces Positive Results for Colon Cancer

LOS ANGELES, CA -- (Marketwired) -- 03/30/17 -- (OTCQB: VBIO) ("Vitality" or the "Company"), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it has positive results indicating a new use for the Company''s proprietary prodrug cannabinoid delivery platform.Multiple colon cancer cell types were screened ...


30.03.2017

Vitality Biopharma Announces Proprietary THC Pharmaceutical with Greatly Decreased Psychoactivity

LOS ANGELES, CA -- (Marketwired) -- 03/02/17 -- (OTCQB: VBIO) ("Vitality" or the "Company"), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it has created a library of proprietary glycosides of THC (delta-9-tetrahydrocannabinol), the main psychoactive chemical found in cannabis or marijuana, which enable targ ...


02.03.2017

Vitality Biopharma Publishes Scientific Data on Discovery of Cannabinoid Glycosides

LOS ANGELES, CA -- (Marketwired) -- 02/01/17 -- (OTCQB: VBIO) ("Vitality Biopharma", "Vitality", or the "Company"), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced the publication of a scientific manuscript that details internal research efforts including the discovery and production of cannabinoid glyc ...


01.02.2017

Vitality Biopharma to Present at Biotech Showcase 2017

LOS ANGELES, CA -- (Marketwired) -- 01/09/17 -- (OTCQB: VBIO) ("Vitality Biopharma," "Vitality," or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it will present at the Ninth Annual Biotech Showcase 2017 Conference, on January 11, at the Hilton San Francisco Union Square.Company CE ...


09.01.2017

Immune Therapeutics Statement on the Death of Christopher Pearce, Founder and Chief Operating Officer

ORLANDO, FL -- (Marketwired) -- 12/12/16 -- Immune Therapeutics, Inc. (OTCQB: IMUN) ("Immune Therapeutics"), a clinical-stage biotech company providing immunotherapy solutions for the treatment of autoimmune disease and cancer, today announced with immense sadness the passing of Christopher Pearce, one of the founders of Immune Therapeutics and its chief operating officer. Mr. Pearce passed away after a 10-year battle with cancer."This is a very sad time for all of us at Immune T ...


12.12.2016

Vitality Biopharma Advances Cannabosides for Treatment of Narcotic Bowel Syndrome

LOS ANGELES, CA -- (Marketwired) -- 11/16/16 -- (OTCQB: VBIO) ("Vitality" or the "Company"), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it is advancing its cannabosides pharmaceuticals for treatment of narcotic bowel syndrome, a severe form of opiate-induced abdominal pain.Every day more than 650,000 op ...


16.11.2016

Vitality Biopharma Announces International Patent Filing for Cannabinoid Pharmaceuticals

LOS ANGELES, CA -- (Marketwired) -- 11/09/16 -- (OTCQB: VBIO) ("Vitality" or the "Company"), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced the filing of an international PCT patent application, a milestone in its development of a platform of cannabinoid pharmaceuticals.The Patent Cooperation Treaty (PCT) is an ...


09.11.2016

Vitality Biopharma Reports on Initial Cannabinoid Drug Formulation Studies

LOS ANGELES, CA -- (Marketwired) -- 10/19/16 -- (OTCQB: VBIO) ("Vitality Biopharma," "Vitality," or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced results of recent drug formulation studies that documented substantial modifications to key physiochemical properties of cannabinoids through ...


19.10.2016

Vitality Biopharma Develops Cannabinoid Alternatives to Opiate Prescription Pain Medications

LOS ANGELES, CA -- (Marketwired) -- 09/13/16 -- (OTCQB: VBIO) ("Vitality" or the "Company"), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, wishes to advise that a written by Robert Brooke, Company CEO, sheds new light on key factors in the fight against the increasing epidemic of prescription painkiller related deaths.In his ...


13.09.2016

Vitality Biopharma to Present at Rodman & Renshaw 18th Annual Global Investment Conference

LOS ANGELES, CA -- (Marketwired) -- 09/12/16 -- (OTCQB: VBIO) ("Vitality" or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders announced today that Company CEO, Robert Brooke will be presenting at the Rodman & Renshaw 18th Annual Global Investment Conference to be held September 12, 2016, at the Lotte New York Pa ...


12.09.2016

Vitality Biopharma Announces Expansion of Prodrug Pharmaceutical Portfolio

LOS ANGELES, CA -- (Marketwired) -- 08/24/16 -- (OTCQB: VBIO) ("Vitality" or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced a significant expansion of its glycoside prodrug intellectual property portfolio through the filing of U.S. patent application 62/363,808, which expands upon two previous pat ...


24.08.2016

Vitality Biopharma Begins Trading Under New Stock Symbol "VBIO"

LOS ANGELES, CA -- (Marketwired) -- 08/17/16 -- (OTCQB: VBIO) ("Vitality" or the "Company"), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, is pleased to announce that effective immediately, its common stock now trades on the over-the-counter market under the symbol "VBIO."Trading of the company''s stock und ...


17.08.2016

Vitality Biopharma Advances Cannabosides for Treatment of Inflammatory Bowel Disease

LOS ANGELES, CA -- (Marketwired) -- 07/27/16 -- (OTCQB: STVFD) ("Vitality" or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced updates to its clinical development plans including the advancement of cannabosides for the treatment of inflammatory bowel disease.Vitality Biopharma has developed a new cl ...


27.07.2016

Pain Sufferers Find Relief With Scientifically Studied Celadrin

KEARNY, NJ -- (Marketwired) -- 07/26/16 -- It''s the leading cause of disability in the United States and more than half of those with the disorder are under the age of 65. Arthritis affects more than 52 million Americans and can be painful to manage, as there is no medical cure other than joint replacement. Inflammatory response supplements containing the clinically studied Celadrin ingredient have been proven to provide pain relief with additional benefits of restoring fluids that c ...


26.07.2016

Vitality Biopharma Name Change and Corporate Actions Receive Shareholder Approval

LOS ANGELES, CA -- (Marketwired) -- 07/19/16 -- (OTCQB: STVF) ("Vitality" or the "Company"), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced shareholder approval and the effective date of a 1-for-10 reverse stock split and a concurrent name change from Stevia First Corp. to Vitality Biopharma, Inc.The reverse sto ...


19.07.2016

Vitality Biopharma to Present at LD Micro and BIO Conferences

LOS ANGELES, CA -- (Marketwired) -- 06/01/16 -- Vitality Biopharma, Inc. (OTCQB: STVF), a company dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that Company CEO Mr. Robert Brooke will be presenting and meeting with investors at the upcoming 2016 LD Micro Invitational and BIO International Conference in June.Vitality Biopharma to present on Tuesd ...


01.06.2016

Launch of Vitality Biopharma for Cannabinoid Prodrug Pharmaceutical Development

LOS ANGELES, CA -- (Marketwired) -- 05/09/16 -- (OTCQB: STVF) (the "Company") is pleased to announce that it is changing its name to Vitality Biopharma, Inc. and that the Company will be dedicated to development of cannabinoid prodrug pharmaceuticals, and unlocking the power of cannabinoids for treatment of serious neurological and inflammatory disorders.In a recent shareholder letter available on the new corporate website at: , the Company''s CEO, Robert Brooke, stated, &q ...


09.05.2016

Turmeric Is One Of The Anti-inflammatory Foods Recommended for Fighting Behcet’s Disease

Orlando, FL– March 9, 2016 – Inflammation is thought to be one of the major culprits in the development of a range of medical conditions. This is why more and more people are consuming anti-inflammatory foods and ingredients such as turmeric to improve their immunity. Even in conditions such as Behcet’s disease, turmeric is highly recommended due to its anti-inflammatory properties. Turmeric has long been popularized by its therapeutic benefits, which are thought to come from its phytochemical ...


11.03.2016

Glucosamine One Of The Best Natural Remedies For Inflammatory Bowel Disease

Orlando, FL – January, 2016 – Today, there many conditions that reduce not just the health of many people but also the quality of their lives, and this includes inflammatory bowel disease. There are medications to help sufferers fight the pain caused by the condition. However, there are also natural alternatives believed to be helpful for IBD. Glucosamine is thought to be one of the best natural remedies for inflammatory bowel disease. While this natural alternative is a popular remedy for arth ...


12.01.2016

Precautions On The Use of NSAIDs Finally Revealed

Orlando, FL– December 24, 2015 – Nonsteroidal anti-inflammatory drugs are some of the most popular pain relief drugs used by arthritis sufferers. They work by reducing pain, and can also decrease inflammation at higher doses. Unfortunately, using these medications carries along certain disadvantages. Precautions on the use of NSAIDs are finally revealed. These medications are designed to reduce pain. They help improve the quality of life of individuals who suffer from arthritis. Without pain, t ...


26.12.2015

Turmeric Is One Of The Best Anti-Inflammatory Foods For Familial Mediterranean Fever

Orlando, FL – December 18, 2015 – Today, more and more people are improving their diet and lifestyle to improve their overall health. However, there are hereditary conditions and many individuals are genetically predisposed to them. One of the genetic disorders is the Familial Mediterranean fever, otherwise known as the recurrent polyserotisis. Turmeric is one of the best anti-inflammatory foods for Familial Mediterranean fever. This genetic disorder causes swelling in the abdomen and lungs. It ...


18.12.2015

Anti-Inflammatory Diet Highly Recommended Over The Use Of Pharmaceutical Drugs

Orlando, FL– December 03, 2015 – Individuals who suffer from pain due to conditions such as arthritis often resort to the use of pain relief drugs. However, the use of these medications has been associated with a variety of side effects. The good news is that there is a particular dietary regimen that is believed to be helpful among individuals who suffer from inflammation. Anti-inflammatory diets are highly recommended over the use of pharmaceutical drugs. Inflammation is widely associated wi ...


05.12.2015

New Study Uncovers Link between Inflammatory Response and Saturated Fat Intake

In a freshly published study, researchers reveal new findings that show how consuming a diet low in saturated fats, but high in monounsaturated fats, drastically reduces the active inflammatory response. This new discovery could change the way inflammatory diseases like atherosclerosis are treated and sheds new light on the influence of obesity in chronic health conditions. Researchers now believe that there is sufficient evidence to prove that over-consumption of saturated fats causes a severe ...


29.09.2015

Clinically Proven Celadrin Provides Relief to Chronic Pain Sufferers

KEARNY, NJ -- (Marketwired) -- 09/22/15 -- Each September, Pain Awareness Month sheds light on the nearly 100 million Americans who experience chronic pain -- a number greater than those who have been diagnosed with diabetes, heart disease and cancer combined. Chronic pain is problematic to treat using traditional medications and costly, with as much as $635 billion spent per year in the United States for medical treatment and lost productivity, according to the Institute of Medicine of The Nat ...


22.09.2015

Qu Biologics Begins Research Collaboration with Dr. Bruce Vallance at the University of British Columbia to Study SSI Treatment for Inflammatory Bowel Disease

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 07/14/15 -- ., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore normal immune function in the targeted diseased organ, announced today it has begun a research collaboration with the laboratory of .Dr. Vallance''s team will be studying the therapeutic effects of Qu Biologics'' SSI treatment for inflammatory bowel disease (Crohn''s disease and ulcerative colitis) in a mouse mo ...


14.07.2015

Qu Biologics Opens Clinical Trial Sites in Edmonton and Toronto for Crohn''s Disease Clinical Trial

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 04/24/15 -- ., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore the body''s normal immune function in the targeted diseased organ, announced today it has opened two new clinical trial sites in Edmonton, Alberta and Toronto, Ontario to enroll participants in its Crohn''s disease clinical trial.Qu Biologics'' Crohn''s disease clinical trial is a randomized, placebo-c ...


24.04.2015

Nutra Pharma Provides Updates for the Marketing of Its All-Natural Pain Reliever, Nyloxin(R)

CORAL SPRINGS, FL -- (Marketwired) -- 11/11/13 -- Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that New Vitality, a marketing and distribution company, has begun filming commercials to begin their advertising campaign for the Company's all-natural, non-addictive pain reliever -- ®.Nyloxin® is a homeopathic drug that utilizes ...


11.11.2013

Amazon.com - The Best Diet Cookbooks Seller With Worldwide Reputation

FOR IMMEDIATE RELEASE Obviously it’s better to take comfort in foods that one regularly takes. However risks are you'll regularly still turn to food for comfort. Perhaps you cherish the taste and composition of frozen yogurt or chocolate as it melts in your mouth. Perhaps you pick pizza in light of the fact that it tops you off and makes you feel warm inside. Possibly there's a food that helps you to remember the great times in your existence or one which dependably greatly improves ...


01.11.2013

Amazon.com Has Become The Best Source Of Wonderful Anti Inflammatory Food Recipes

FOR IMMEDIATE RELEASE Consuming Anti Inflammatory Foods appears to be an all-encompassing method for expanding the nature of an individual's life over a long time. Numerous old aged people have taken these foods to get rid of their joint pain, alzimers. As the number of the diseases is ascending day by day using the foods of anti inflammatory is great. Including this type of foods in the eating regimens is very important. With this mission the amazon.com has introduced some Diet Books an ...


01.11.2013

Can-Fite BioPharma Successfully Concludes $6,000,000 Public Offering With an Over-Subscription of 300%

PETACH TIKVA, ISRAEL -- (Marketwired) -- 10/25/13 -- Can-Fite BioPharma (TASE: CFBI) (OTCQB: CANFY), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today it has successfully closed on a public offering of its common shares on the Tel Aviv Stock Exchange in the amount of approximately U.S. $6,000,000 with an over-subscription of 300%. The offering was priced at New Israeli Shekel (NIS) 5,800 per unit. Each unit ...


25.10.2013

Nutra Pharma Announces Updated Interviews With Wall Street Buy Sell Hold

CORAL SPRINGS, FL -- (Marketwired) -- 10/22/13 -- (OTCQB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that their Chief Executive Officer, Rik J Deitsch, was interviewed by Chris Castaldo of Wall Street Buy Sell Hold. The interview is an update to the previous one posted in August and provides an outline for the short, mid-term and long-term goals of the compan ...


22.10.2013

Can-Fite BioPharma's CF101 Drug Selected as one of the "Top Autoimmune/Anti-Inflammatory Disease Projects to Watch" by Elsevier Business Intelligence

PETACH TIKVA, ISRAEL -- (Marketwired) -- 10/15/13 -- Ltd. (TASE: CFBI), (OTCQB: CANFY), a biotechnology company developing a pipeline of small molecule drugs that address inflammatory and cancer diseases, announced today that Can-Fite's was selected as one of the by , the publisher of and , and a global leader in the field of healthcare industry information."Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our com ...


15.10.2013

Can-Fite BioPharma to Present Its Liver Cancer Drug at the 18th World Congress on Advances in Oncology in Greece

PETACH TIKVA, ISRAEL -- (Marketwired) -- 10/10/13 -- . (TASE: CFBI), (OTCQB: CANFY), a biotechnology company developing a pipeline of small molecule drugs that address inflammatory and cancer diseases, announced today that the Company will be presenting its cancer drug, CF102, at the , which is taking place in Crete, Greece on October 10th through 12th 2013. Can-Fite's CEO Dr. Pnina Fishman will be presenting on Friday, October 11 at 12:00 pm. The event is hosted by , a leading publishing ...


10.10.2013

Nutra Pharma Announces TCN's Full Launch of Their Nyloxin(R) Distribution Model

CORAL SPRINGS, FL -- (Marketwired) -- 10/08/13 -- (OTCQB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is providing updates on the sales and marketing activities of TCN, a distributor of Nutra Pharma's over-the-counter (OTC) pain reliever, .In September 2012, Nutra Pharma announced the beginning of distribution efforts by the TCN group of direct distributors. Since that time, TCN has worked diligently to int ...


08.10.2013

Can-Fite's Subsidiary OphthaliX to Present at Ophthalmology Futures European Forum

PETACH TIKVA, ISRAEL -- (Marketwired) -- 10/02/13 -- Ltd. (TASE: CFBI), (OTCQB: CANFY), a biotechnology company developing a pipeline of small molecule drugs that address inflammatory and cancer diseases, announced today that Dr. Sari Fishman, the Director of Clinical Affairs of . (OTCQB: OPLI), its subsidiary, will deliver a company presentation at the in Amsterdam, The Netherlands. The conference brings together a diverse panel of key members of the ophthalmology community, including those ...


02.10.2013

Can-Fite CEO Pnina Fishman Interviewed on CorporateProfile.com

PETACH TIKVA, ISRAEL -- (Marketwired) -- 09/23/13 -- (TASE: CFBI), (PINKSHEETS: CANFY), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the Company's CEO Dr. Pnina Fishman was recently interviewed on CorporateProfile.com.In the interview Dr. Fishman spoke about Can-Fite listing its shares in the U.S., the Company's drug development pipeline, and the scientific basis for Can-Fite's pla ...


23.09.2013

DGAP-News: Press Release: 4SC Discovery and LEO Pharma announce exclusive research and license agreement for inflammatory skin diseases

DGAP-News: 4SC AG / Key word(s): Agreement/Alliance Press Release: 4SC Discovery and LEO Pharma announce exclusive research and license agreement for inflammatory skin diseases 26.02.2013 / 07:30 --------------------------------------------------------------------- Press Release 4SC Discovery and LEO Pharma announce exclusive research and license agreement for inflammatory skin diseases Planegg-Martinsried, Germany and Ballerup, Denmark, 26 February 2013 - 4SC AG (Frankfurt, Prime Standard: ...


26.02.2013

spalook.com Announces the Addition of Cosmetics 27

GOLD RIVER, CA -- (Marketwire) -- 01/23/13 -- , one of the most trusted online sources for high-performance luxury skin care and beauty essentials, has added the skin care brand to its assortment of premium beauty products.Cosmetics 27 by M.E. SkinLab is uncompromisingly effective skin care. This short line of ethical products is free of any parabens, phenoxyethanol, petrochemical derivatives, silicone and colorant. Instead, Cosmetics 27 is the balance between biotechnology, nature, and luxury ...


23.01.2013

DGAP-News: Press Release 4SC: Clinical data with 4SC's compound Vidofludimus in inflammatory bowel disease published in peer-reviewed scientific journal

DGAP-News: 4SC AG / Key word(s): Miscellaneous Press Release 4SC: Clinical data with 4SC's compound Vidofludimus in inflammatory bowel disease published in peer-reviewed scientific journal 02.11.2012 / 07:30 --------------------------------------------------------------------- Press Release Clinical data with 4SC's compound Vidofludimus in inflammatory bowel disease published in peer-reviewed scientific journal Planegg-Martinsried/Germany, 2 November 2012 - 4SC AG (Frankfurt, Pri ...


02.11.2012



All members: 9 438
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 89


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.